These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra). TreatmentUpdate; 2008 Jan; 20(1):1-2. PubMed ID: 18320690 [No Abstract] [Full Text] [Related]
13. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART. Bongiovanni M; Chiesa E; Monforte Ad; Bini T Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401 [No Abstract] [Full Text] [Related]
14. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor]. Ershov FI; Kas'ianova NV; Vasil'ev AN Antibiot Khimioter; 2002; 47(11):27-9. PubMed ID: 12698577 [No Abstract] [Full Text] [Related]
15. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. Resino S; Bellón JM; Muñoz-Fernández MA; J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377 [No Abstract] [Full Text] [Related]
19. A king in the CASTLE? Optimum initial HIV protease inhibitor. Torti C; Frank I Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849 [No Abstract] [Full Text] [Related]
20. FDA notifications. HIV-1 adult treatment guidelines are updated. AIDS Alert; 2006 Jun; 21(6):71. PubMed ID: 16795141 [No Abstract] [Full Text] [Related] [Next] [New Search]